Melanoma: Our Clinical Trials

Clinical trials are research studies that evaluate the safety and effectiveness of new treatments and diagnostic tools. If you are eligible to participate in a clinical trial, you may have access to new melanoma therapies not widely available elsewhere.

As a result of clinical trial findings, MSK has made major advances in two areas in particular: the development of immunotherapies that boost your immune system’s ability to fight the cancer (such as ipilimumab) and targeted therapies that home in on specific defects in your individual cancer, blocking the growth of cancer cells while sparing most normal, healthy cells.

We continue to conduct trials with ipilimumab and other experimental immunotherapies and targeted therapies and are expert at selecting investigational therapies most likely to benefit you.

When you speak to us about participating in a melanoma clinical trial, we’ll discuss how the process works. During the informed consent process — before you decide whether you want to join — we’ll also tell you if the trial you are considering involves some participants receiving a placebo (a pill, liquid, or powder that mimics the look of the treatment drug but has no effect).

Choose from the list of current studies below to learn more about a particular study. 

Showing 31 trials
Title Investigatorsort icon
A Phase I Study of an mRNA-Modified Dendritic Cell Vaccine in Patients with Melanoma
[Protocol 10-229]
Young, James, MD
A Phase I Study of AEB071 in Patients with Metastatic Uveal Melanoma
[Protocol 11-167]
Wolchok, Jedd, MD, PhD
A Study of the Biologic Effects of Nivolumab (BMS-936558) in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-231]
Wolchok, Jedd, MD, PhD
A Phase I Study of IMCgp100 in Patients with Advanced Melanoma
[Protocol 14-152]
Wolchok, Jedd, MD, PhD
A Phase I Study of BVD-523 in Patients with Advanced Cancers
[Protocol 13-254]
Varghese, Anna, MD
A Phase I Study of MEDI4736 in Patients with Advanced Solid Tumors
[Protocol 12-179]
Segal, Neil, MD, PhD
A Phase I Study of Lirilumab plus Nivolumab in Patients with Advanced Solid Tumors
[Protocol 12-224]
Segal, Neil, MD, PhD
A Phase III Study of MEK162 versus Dacarbazine in Patients with Inoperable or Metastatic Melanomas with NRAS Q61 Mutations: The NEMO Trial
[Protocol 13-083]
Postow, Michael, MD
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
[Protocol 13-102]
Postow, Michael, MD
A Phase Ib Study of AEB071 and MEK162 in Patients with Advanced Uveal Melanoma
[Protocol 13-172]
Postow, Michael, MD
Expanded Access to MK-3475 for Patients with Metastatic Melanoma with Few to No Treatment Options
[Protocol 14-093]
Postow, Michael, MD
A Pilot Study of PET Imaging of Solid Tumors Using Radioactive Iodine-Labeled Hu3F8
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-147]
Modak, Shakeel, MD
A Phase II Study of Dasatinib in Patients with Inoperable Locally Advanced or Metastatic c-KIT-Positive Acral or Mucosal Melanoma
[Protocol 13-100]
Leitao, Mario, MD
A Phase I Study of HDM201 in Patients with Advanced Cancers and a Normal TP53 Gene
[Protocol 14-139]
Hyman, David, MD
A Phase I Study of CB-839 in Patients with Advanced Solid Tumors
[Protocol 14-111]
Harding, James, MD
A Phase I Study of Vemurafenib in Adolescents with Inoperable Stage IIIC/IV Melanoma with V600 BRAF Mutations
Newly Diagnosed & Relapsed/Refractory
[Protocol 11-198]
Dunkel, Ira, MD
A Phase II Study of Ipilimumab in Children and Adolescents with Stage III/IV Inoperable Melanoma
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-043]
Dunkel, Ira, MD
A Phase I/IIA Study of Dabrafenib in Children with Advanced BRAF Mutation-Positive Solid Tumors
[Protocol 13-016]
Dunkel, Ira, MD
A Phase II Study of Dabrafenib After Surgery in Patients with BRAF V600 Mutation-Positive Stage IIIC Melanoma
[Protocol 12-124]
Chapman, Paul, MD
A Phase II Study of LGX818 Given in a Pulsatile Schedule to Patients with Stage III or IV Melanoma with a BRAF Mutation
[Protocol 13-053]
Chapman, Paul, MD
A Phase II Study of Trametinib with and without GSK2141795 in Patients with Advanced Uveal Melanoma
[Protocol 13-144]
Chapman, Paul, MD
A Phase II Clinical Trial of Trametinib plus GSK2141795 in Patients with Melanoma Containing a Normal BRAF Gene
[Protocol 13-258]
Chapman, Paul, MD
A Phase II Study of Dacarbazine with and without Selumetinib to Treat Metastatic Uveal Melanoma
[Protocol 14-033]
Chapman, Paul, MD
A Phase II Study of Crizotinib in Patients with High-Risk Uveal Melanoma
[Protocol 14-063]
Chapman, Paul, MD
An Expanded Access Program with Nivolumab and Ipilimumab for Patients with Inoperable or Metastatic Melanoma
[Protocol 14-200]
Chapman, Paul, MD
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230)) in Patients with Advanced Uveal Melanoma
[Protocol 10-123]
Carvajal, Richard, MD
A Phase II Study of Vorinostat for Metastatic Uveal Melanoma
[Protocol 12-027]
Carvajal, Richard, MD
Targeted Silica Nanoparticles for Image-Guided Sentinel Lymph Node Mapping During Surgery in Patients with Melanoma of the Head and Neck
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-249]
Bradbury, Michelle, MD
A Phase III Study of Surgery Followed by Radiation Therapy or Observation in Patients with Neurotropic Melanoma of the Head and Neck
[Protocol 13-248]
Barker, Christopher, MD
A Phase I Study of AM0010 in Patients with Advanced Solid Tumors
[Protocol 13-224]
Autio, Karen, MD
A Phase II Study of Ipilimumab Plus Isolated Limb Infusion with Melphalan and Dactinomycin to Treat Advanced Unresectable Melanoma of the Extremity
[Protocol 10-101]
Ariyan, Charlotte, MD